Nalu Medical is a technology company.
Nalu Medical has raised $85.0M across 1 funding round.
Nalu Medical has raised $85.0M in total across 1 funding round.
Nalu Medical is a Carlsbad, California-based medical technology company that develops and commercializes the Nalu Neurostimulation System, a minimally invasive neurostimulation platform for treating chronic neuropathic pain through spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS).[1][2][4] The system features a miniaturized, battery-free implantable pulse generator (mIPG)—27 times smaller than leading competitors—powered wirelessly by an external Therapy Disc and controlled via a smartphone app, delivering advanced waveforms to interrupt pain signals before they reach the brain.[1][2][3] It serves patients with severe, intractable chronic pain in areas like the shoulder, lower back, and knee, while reducing healthcare costs and eliminating battery replacement surgeries.[2][3][6] Nalu has raised $246.6M, achieved recognitions like R&D Magazine's top 100 products in 2021 and #19 on the 2023 Deloitte Technology Fast 500, and was recently acquired by Boston Scientific in 2025.[2][3][4]
Founded in 2014, Nalu Medical emerged from a team of seasoned entrepreneurs, engineers, and scientists aiming to modernize medical devices for poorly treated conditions like chronic pain.[4][8] Headquartered in Carlsbad, California, the company developed its core innovation—a micro-IPG leveraging proprietary nPower microchip technology—to address unmet needs in neurostimulation, such as device size, invasiveness, and patient control.[1][8] Early traction came from FDA clearances for SCS and PNS, clinical validations showing cost reductions and pain relief, and accolades that propelled growth through Series E funding, culminating in Boston Scientific's acquisition agreement announced October 17, 2025.[2][3][4][9]
Nalu rides the wave of advancing peripheral nerve stimulation (PNS), a rapidly evolving field emphasizing miniaturization, wireless tech, and less invasive chronic pain therapies amid rising demand for opioid alternatives.[6] Timing aligns with post-pandemic healthcare cost pressures and neuromodulation growth, where Nalu's innovations lower utilization costs while expanding access for intractable pain affecting millions.[2][6] Market forces like FDA clearances and payer interest favor its value proposition, influencing the ecosystem by setting benchmarks for micro-IPGs and prompting competitors toward external power models; its Boston Scientific acquisition accelerates integration into larger medtech portfolios, potentially standardizing PNS for broader adoption.[3][7]
With Boston Scientific's 2025 acquisition, Nalu's platform gains global scale, likely accelerating R&D into new indications and Therapy Disc iterations for even broader PNS applications.[3][7] Trends like AI-driven waveforms, expanded wearables, and value-based care will shape its path, evolving Nalu from innovator to mainstream chronic pain staple—ultimately redefining minimally invasive neurostimulation as the gold standard for neuropathic relief.[2][6] This positions it to transform patient lives at the intersection of medtech miniaturization and personalized therapy.
Nalu Medical has raised $85.0M in total across 1 funding round.
Nalu Medical's investors include Amplify Partners, B Capital Group, Felicis Ventures, Great Oaks Venture Capital, Slow Ventures, Tencent Holdings, Y Combinator, Joe Greenstein, Kenny Van Zant.
Nalu Medical has raised $85.0M across 1 funding round. Most recently, it raised $85.0M Series E in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $85.0M Series E | Amplify Partners, B Capital Group, Felicis Ventures, Great Oaks Venture Capital, Slow Ventures, Tencent Holdings, Y Combinator, Joe Greenstein, Kenny Van Zant |